Robin Barbour
About Robin Barbour
Robin Barbour serves as the Head of Antibody and Assay Development at Prothena Corporation, where he focuses on assay methods for neurodegenerative diseases. With extensive experience in bioanalysis and a history of leadership roles in prominent pharmaceutical companies, he holds several patents related to Alzheimer's and Parkinson's diseases.
Current Role at Prothena Corporation
Robin Barbour serves as the Head of Antibody and Assay Development at Prothena Corporation since 2012. In this role, Barbour manages the development of assays and oversees the contract research organizations (CROs) that conduct these assays for clinical trials. Barbour's work focuses on advancing therapeutic strategies for neurodegenerative diseases, particularly through the development of antibody-based treatments.
Previous Experience at Neotope Biosciences
Prior to joining Prothena, Robin Barbour worked at Neotope Biosciences, a division of Elan Pharmaceuticals, from 1987 to 2009. During this 22-year tenure, Barbour held the position of Highest Associate Director of Target Validation. Barbour led significant projects, including the development of the murine version of Tysabri for Multiple Sclerosis and Bapineuzumab for Alzheimer’s Disease.
Research Contributions and Patents
Robin Barbour holds several patents and patent applications related to assay methods for Alzheimer’s Disease, Parkinson’s Disease, and Immunogenicity monitoring. Barbour has contributed to research on amyloid-directed monoclonal antibodies and has co-authored studies on amyloid imaging and therapy. Additionally, Barbour has participated in studies related to α-synuclein immunization in Parkinson's disease models.
Education and Academic Background
Robin Barbour studied at the University of California, Davis, where Barbour earned a Bachelor of Science degree in Biochemistry from 1978 to 1981. This educational background provided a foundation for Barbour's extensive career in bioanalysis and assay development in the pharmaceutical industry.
Role at JANSSEN Alzheimer Immunotherapy
From 2009 to 2012, Robin Barbour served as the Director of Research at JANSSEN Alzheimer Immunotherapy. In this position, Barbour was involved in research focused on Alzheimer's disease, contributing to the understanding and development of therapeutic strategies aimed at addressing this condition.